Avita Medical (ASX:AVH) said last week it tapped former Novartis (NYSE:NVS) global biz dev & licensing chief scientific officer Dr. Michael Perry as its new chief executive officer, replacing resigning CEO Adam Kelliher. Dr. Perry served as a non-exec director of Avita since Feb 2013, according to the company, and held positions with Novartis including chief scientific […]
iRhythm Technologies said it closed a $16 million Series D round for its Zio wearable heart monitor, saying it plans to use the proceeds to further its commercial footprint and research & development efforts.
Led by Norwest Venture Partners, which added partner Casper de Clercq to iRhythm’s board, the latest financing including contributions from existing backers New Leaf Ventures, Synergy Life Science Partners and Kaiser Permanente Ventures.
On-Q-ity, which raised a $26 million Series A round back in December 2009, quietly folded its tents last year after an unsuccessful bid to develop its technology for personalized cancer detection.
Bruce Booth, a partner at Atlas Ventures, 1 of the VC shops that backed the company (and a member of On-Q-ity’s board), detailed the reasons behind the decision this week on his blog, Life Sci VC.